Rapid Micro Biosystems, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Rapid Micro Biosystems, Inc. (RPID) on December 23, 2021, reporting events occurring on December 17, 2021. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Lowell, Massachusetts. Its Class A Common Stock trades on The Nasdaq Global Select Market.
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on corporate governance changes.
Material Changes
The primary material change reported is the appointment of Inese Lowenstein to the Board of Directors and the Audit Committee. Key details include:
- Role: Class III Director and Audit Committee member.
- Term: Expires at the 2024 annual meeting of stockholders.
- Independence: The Board determined Ms. Lowenstein meets independence requirements under Nasdaq and Exchange Act standards.
- Background: Ms. Lowenstein brings over 20 years of experience, including roles at Danaher Corporation (Senior Talent Advisor, former President of SCIEX), Merck KGaA, and EMD Millipore.
Compensation and Equity Grant
Ms. Lowenstein will receive standard cash and equity compensation for non-employee directors. Specifically, she was granted an option to purchase 25,000 shares of Class A Common Stock under the 2021 Incentive Award Plan:
- Exercise Price: $11.23 per share (closing price on the date of grant).
- Vesting Schedule: 36 substantially equal monthly installments, contingent on continued service.
- Indemnification: An indemnification agreement was executed in the standard form.
Outlook, Risks, and Contingencies
The filing does not provide management commentary on business outlook, specific risks, or contingencies beyond the standard disclosure that there are no undisclosed arrangements or family relationships requiring disclosure under Item 404(a) of Regulation S-K.
Key Facts for Investor Verification
- Verify the vesting schedule and exercise price of the 25,000 share option granted to Inese Lowenstein.
- Confirm Ms. Lowenstein's independence status and Audit Committee qualifications as disclosed.
- Review the attached Press Release (Exhibit 99.1) for additional context on the appointment.
- Note that this filing contains no financial performance data; refer to the most recent 10-K or 10-Q for financial metrics.